{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:20:40Z","timestamp":1772184040472,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"DOI":"10.7759\/cureus.104355","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:54:03Z","timestamp":1772182443000},"source":"Crossref","is-referenced-by-count":0,"title":["First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series"],"prefix":"10.7759","author":[{"given":"Daisuke","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiharu","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Shirotake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2025.1886","article-title":"Enhancing bladder cancer awareness and knowledge through multifaceted community engagement in Egypt: a cross-sectional study","volume":"19","author":"Hammad AA","year":"2025","unstructured":"Hammad AA, Ezzat O, Filicevas A, et al.. Enhancing bladder cancer awareness and knowledge through multifaceted community engagement in Egypt: a cross-sectional study. Ecancermedicalscience. 2025, 19:1886. 10.3332\/ecancer.2025.1886","journal-title":"Ecancermedicalscience"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles T","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al.. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020, 383:1218-30. 10.1056\/NEJMoa2002788","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al.. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024, 390:875-88. 10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"National Comprehensive Cancer Network. Bladder cancer. (2025). Accessed. February 20, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles T","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, et al.. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024, 35:485-90. 10.1016\/j.annonc.2024.03.001","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad246","article-title":"Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment","volume":"116","author":"Gupta S","year":"2024","unstructured":"Gupta S, Andreev-Drakhlin A, Fajardo O, Fass\u00f2 M, Garcia JA, Wee C, Schr\u00f6der C. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment. J Natl Cancer Inst. 2024, 116:547-54. 10.1093\/jnci\/djad246","journal-title":"J Natl Cancer Inst"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.04.008","article-title":"Clinical outcomes of platinum-ineligible patients with advanced urothelial carcinoma treated with first-line PD1\/L1 inhibitors","volume":"19","author":"Pond GR","year":"2021","unstructured":"Pond GR, Agarwal A, Ornstein M, et al.. Clinical outcomes of platinum-ineligible patients with advanced urothelial carcinoma treated with first-line PD1\/L1 inhibitors. Clin Genitourin Cancer. 2021, 19:425-33. 10.1016\/j.clgc.2021.04.008","journal-title":"Clin Genitourin Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.10.016","article-title":"Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction","volume":"44","author":"Litt HK","year":"2026","unstructured":"Litt HK, Mamtani R, Chow RD. Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol. 2026, 44:118.e1-5. 10.1016\/j.urolonc.2025.10.016","journal-title":"Urol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10481","article-title":"Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: case report","volume":"5","author":"Mizuno T","year":"2025","unstructured":"Mizuno T, Kobari Y, Ito H, et al.. Safety of enfortumab vedotin plus pembrolizumab in hemodialysis patients with metastatic urothelial carcinoma: case report. Cancer Diagn Progn. 2025, 5:647-51. 10.21873\/cdp.10481","journal-title":"Cancer Diagn Progn"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.04.005","article-title":"Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction","volume":"40","author":"Kita Y","year":"2022","unstructured":"Kita Y, Ito K, Kanda S, et al.. Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. Urol Oncol. 2022, 40:410.e11-8. 10.1016\/j.urolonc.2022.04.005","journal-title":"Urol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15101","article-title":"Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: efficacy, safety, and evidence for trial-unfit patients","volume":"30","author":"Ito K","year":"2023","unstructured":"Ito K, Kita Y, Kobayashi T. Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: efficacy, safety, and evidence for trial-unfit patients. Int J Urol. 2023, 30:696-703. 10.1111\/iju.15101","journal-title":"Int J Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102426","article-title":"Impact of impaired renal function on the efficacy and safety of enfortumab vedotin monotherapy in a multicenter real-world cohort of patients with metastatic urothelial cancer: YUSHIMA study","volume":"23","author":"Fukushima H","year":"2025","unstructured":"Fukushima H, Nakamura Y, Tanaka H, et al.. Impact of impaired renal function on the efficacy and safety of enfortumab vedotin monotherapy in a multicenter real-world cohort of patients with metastatic urothelial cancer: YUSHIMA study. Clin Genitourin Cancer. 2025, 23:102426. 10.1016\/j.clgc.2025.102426","journal-title":"Clin Genitourin Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01089-2","article-title":"Pembrolizumab in patients with advanced urothelial carcinoma with ECOG performance status 2: a real-world study from the ARON-2 project","volume":"19","author":"Rizzo A","year":"2024","unstructured":"Rizzo A, Monteiro FS, \u00dcr\u00fcn Y, et al.. Pembrolizumab in patients with advanced urothelial carcinoma with ECOG performance status 2: a real-world study from the ARON-2 project. Target Oncol. 2024, 19:747-55. 10.1007\/s11523-024-01089-2","journal-title":"Target Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469846-first-line-enfortumab-vedotin-plus-pembrolizumab-in-platinum-ineligible-urothelial-carcinoma-a-three-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T08:54:04Z","timestamp":1772182444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469846-first-line-enfortumab-vedotin-plus-pembrolizumab-in-platinum-ineligible-urothelial-carcinoma-a-three-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.104355","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}